Does the 2011 GOLD staging of COPD reflect phenotype and severity of the disease as assessed by CT?

F. Bigazzi, M. Paoletti, E. Torricelli, V. Luzzi, A. Garcea, M. Vannini, L. Corsi, V. Bellino, L. Cestelli, G. Camiciottoli, M. Pistolesi (Florence, Italy)

Source: Annual Congress 2013 –COPD treatment and others
Session: COPD treatment and others
Session type: Thematic Poster Session
Number: 3656
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Bigazzi, M. Paoletti, E. Torricelli, V. Luzzi, A. Garcea, M. Vannini, L. Corsi, V. Bellino, L. Cestelli, G. Camiciottoli, M. Pistolesi (Florence, Italy). Does the 2011 GOLD staging of COPD reflect phenotype and severity of the disease as assessed by CT?. Eur Respir J 2013; 42: Suppl. 57, 3656

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013

COPD: GOLD 2011 and implications for clinical practice
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

Frequency and severity of exacerbations reflect COPD severity, but not COPD phenotype as determined by quantitative CT
Source: International Congress 2014 – Markers
Year: 2014

GOLD staging and grading for predicting one-year mortality in COPD patients with severe exacerbation
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016


Three year follow-up of distribution and stability of patients with COPD according GOLD 2014
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015


Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


COPD comorbidities and risk assessment according to GOLD 2011 revision
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013


Severity of airflow obstruction and multicomponent disease staging of COPD in the real-world primary care in Greece: The AEOLUS study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Cardiovascular comorbidities prevails in the early stages of COPD irrespective of predominant airway or emphysema phenotype
Source: Annual Congress 2013 –COPD treatment
Year: 2013

The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015


GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


Significance of quantitative radiological phenotypes of COPD on BODE index
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


The relationship between presence of small airways disease and baseline characteristics of asthma and COPD patients
Source: International Congress 2016 – Monitoring airway diseases with different tools
Year: 2016



To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013

Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013


Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016


Pulmonary diffusing capacity and the risk of fractures in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – COPD markers
Year: 2014

Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013


Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016

Early phenotypes of chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Different data in COPD
Year: 2015